Needle biopsy is s an advanced technology used in diagnostics to retrieve the suspected tissues for the early diagnosis of several illnesses. These samples are tested and analyzed for assessing the stage of the disease and understand its intensity or existence.
Reduced costs of raw materials and increased production of goods are some of the leading factors driving the global needle biopsy market. Additionally, the prevalence of cancer cases across the globe is propelling the usage of biopsy needles. The key players are also focusing on enhancing the distribution channels to decrease the price pressure. Improved measures by the government to increase awareness and the rising geriatric population are foreseen to contribute to the market growth in the coming years.
The technology used in needle biopsy is a non-invasive technique to detect cancer using liquids like blood, urine, mucus, saliva, and so on from the patient’s body. With the advancement in technology and adoption, a needle biopsy can take over cancer and diagnostic treatments on a wide scale. This technology helps detect the real-time growth of the tumors and is a feasible option. The market is however expected to witness price pressure due to the emergence of several Chinese manufacturing companies.
The global needle biopsy market is segmented into type, utility, application, and region. In terms of type, the global market is divided into core needle biopsy, image-guided biopsy, fine-needle aspiration biopsy, and vacuum-assisted biopsy. On the basis of utility, the global needle biopsy market is bifurcated into reusable and disposable. Based on application, the market is sectioned into inflammation, infection, tumor, and others.
Geographically, the global needle biopsy market is estimated to be led by North America. The US is the leading nation contributing to the market growth within the forecast period owing to the presence of key players, adoption of technology, improved reimbursement policies, and increased expenditure on healthcare. The second place in the market is bagged by Europe owing to rising awareness and an increase in disposable income. Moreover, the adoption of high-priced medical devices and rising implementation of cancer screening programs in the region are propelling the growth.
Asia Pacific region is likely to witness growth owing to increasing research and development activities. In addition, owing to the weak healthcare system and political instability in the Middle East & Africa, the regional market is foreseen to witness sluggish development.
The key players leading the global needle biopsy market are CareFusion Corporation, Boston Scientific Corporation, C. R. Bard, Inc, Hologic, Inc, Medax, Moller Medical GmbH, BD Hakko co. ltd, Argon Medical Devices, Inc., Cook Medical, etc.
To cite, the research team at Aalto University, Finland has innovated an ultrasonic needle to extract more amounts of tissues without causing any complications and pain during the biopsy. The needle is named as AdvaNeedle.